HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact

Genprex announces new branding

September 6, 2011Press Releases

AUSTIN, TX, September 6, 2011 – Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™. “We are establishing the Oncoprex brand in the oncology sector in recognition of our advancing development programs. We anticipate that when approved, Oncoprex will […]

Read More

Genprex announces patent award

July 14, 2011Press Releases

AUSTIN, TX, July 14, 2011 – Genprex, Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services. The patent is one of 23 patents, pending or […]

Read More

Genprex Announces Patent Award for Cancer Suppressors

June 28, 2011Press Releases

AUSTIN, TX, June 28, 2011 – Genprex, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services. U.S. Patent No. 7,902,441 is one of 23 patents, pending […]

Read More

Clinical Trial Data Presented at the 2011 AACR Meeting

April 15, 2011Press Releases

Oncoprex™ Phase I clinical trial data presented at the 2011 Annual Meeting of the American Association for Cancer Research in Orlando, Florida. Dr Charles Lu of MD Anderson Cancer Center presented the award winning abstract and poster describing the phase I, dose escalation trial investigating Oncoprex as a monotherapy in patients with recurrent and metastatic […]

Read More

  • Prev
  • «
  • ‹
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28


Note: When you click on media articles, a new page will open indicating that you are leaving the Genprex, Inc. website and entering a third-party website not affiliated with Genprex Inc. or any of its affiliates. No information contained in a linked site has been endorsed or approved by Genprex, Inc. and Genprex, Inc. is not responsible for the content of such third-party websites.

Categories

  • Acclaim 1
  • Acclaim 2
  • Acclaim 3
  • Blog Posts
  • Clinical Trials
  • Media Coverage
  • Press Releases

Recent Posts

  • Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
  • Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
  • Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
  • Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
  • Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging 

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • November 2021
  • September 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • October 2017
  • July 2017
  • April 2017
  • March 2017
  • January 2017
  • December 2016
  • November 2016
  • August 2016
  • November 2015
  • September 2015
  • May 2014
  • April 2012
  • September 2011
  • July 2011
  • June 2011
  • April 2011
  • May 2010

Tag Cloud

Acclaim-1 Acclaim-2 Acclaim-3 Aging Aldevron Austin Business Journal Big Biz Show cancer CEO Clinical Trials conference Conferences Diabetes Dr. Gittes Events Fast Track Fast Track Designation FDA FDA Fast Track Fitness gene therapy Health Immunotherapies Immunotherapy Insulin KOL Event Lung cancer Manufacturing Media Coverage Nonviral Vector NSCLC Oncology Oncoprex Preclinical Data Presentation Presentations Reqorsa Russell Index Shareholder Letter Small cell lung cancer Tagrisso Tips TUSC2 University of Pittsburgh Video

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress Nov 5
  • Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer Nov 4
  • Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3) Nov 2
  • Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting Oct 28
Designed and Secured by Barsec
Copyright ©2026 all rights reserved.
Home - Privacy Policy - Terms of Use